KEROS THERAPEUTICS IN

Keros Therapeutics to Present at Upcoming Healthcare Conferences

07 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

06 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

04 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

05 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

07 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

27 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

12 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

09 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

07 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

22 May 2023 09:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

11 May 2023 16:01:01 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

04 May 2023 16:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

19 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

03 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

01 Mar 2023 08:00:02 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

12 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

22 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

07 Nov 2022 16:01:00 By Nasdaq GlobeNewswire